XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.24.3

CONCENTRATIONS | 9 Months Ended
--- | ---
Sep. 30, 2024
CONCENTRATIONS |
CONCENTRATIONS | (14) CONCENTRATIONS For the three months ended September 30, 2024, the Company sourced approximately 57% of the supplies for its electrotherapy products from four significant vendors. For the same period in 2023, the Company sourced approximately 57% of the supplies for its electrotherapy products from four significant vendors. Significant vendors provided at least 10% of the total value spent on the Company’s electrotherapy products during the period. For the nine months ended September 30, 2024, the Company sourced approximately 56% of supplies for its electrotherapy products from four significant vendors. For the same period in 2023, the Company sourced approximately 47% of supplies for its electrotherapy products from four significant vendors. At both September 30, 2024 and December 31, 2023, the Company had no gross receivables from any third-party payers that made up over 10% of the net accounts receivable balance.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration